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Abstract
Efficacy and mode of action of mesalazine in the treatment
of diarrhoea-predominant irritable bowel syndrome
(IBS-D): a multicentre, parallel-group, randomised
placebo-controlled trial
Ching Lam,1 Wei Tan,2 Matthew Leighton,2 Margaret Hastings,3
Melanie Lingaya,1 Yirga Falcone,1 Xiaoying Zhou,4 Luting Xu,5
Peter Whorwell,3 Andrew F Walls,4 Abed Zaitoun,6
Alan Montgomery2 and Robin C Spiller1*
1National Institute for Health Research (NIHR) Nottingham Digestive Diseases Biomedical Research
Unit, Nottingham University Hospitals NHS Trust, Nottingham, UK
2Clinical Trials Unit, University of Nottingham, Nottingham, UK
3Neurogastroenterology Unit, University Hospital of South Manchester NHS Foundation Trust,
Manchester, UK
4Immunopharmacology Group, University of Southampton, Southampton, UK
5FRAME Laboratory, University of Nottingham, Nottingham, UK
6Histopathology, Nottingham University Hospitals NHS Trust, Nottingham, UK
*Corresponding author robin.spiller@nottingham.ac.uk
Background: Diarrhoea-predominant irritable bowel syndrome (IBS-D) is a common outcome after
inflammation due to bacterial gastroenteritis. Several studies have shown ongoing immune activation in
the mucosa of patients with IBS-D and a number of studies have suggested that mesalazine slow-release
granule formulation (2 g; PENTASA®, Ferring Pharmaceuticals Ltd) may provide benefit including a
reduction in stool frequency.
Objectives: Our primary aim was to compare the effect of mesalazine with placebo on stool frequency.
Our secondary aims were to assess the effect of mesalazine on abdominal pain, stool consistency, urgency
and satisfactory relief of irritable bowel syndrome (IBS) symptoms.
Design/participants/intervention: We performed a double-blind, randomised placebo-controlled trial of
2 g mesalazine twice daily compared with placebo for 3 months in Rome III criteria patients with IBS-D.
Settings: Participants were recruited from the primary care research network and secondary care hospitals.
Participants were randomised after a 2-week baseline stool diary. All participants completed a 12-week
stool diary and at the end of each week recorded the presence of ‘satisfactory relief of IBS symptoms’.
Those recruited in Nottingham had sigmoid biopsies and/or magnetic resonance imaging of the abdomen
at the start and end of the trial.
Results: A total of 136 patients with IBS-D (82 female, 54 male) were randomised; 10 patients withdrew
from each group. Analysis by intention to treat showed that the mean daily average stool frequency during
weeks 11 and 12 was 2.8 [standard deviation (SD) 1.2] in the mesalazine group and 2.7 (SD 1.9) in the
placebo group, with a group difference of 0.1 (95% confidence interval –0.33 to 0.53); p= 0.66.
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Conclusions: Mesalazine did not improve abdominal pain, stool consistency or percentage with
satisfactory relief compared with placebo during the last 2 weeks’ follow-up. A post hoc analysis in
13 postinfectious patients with IBS appeared to show benefit but this needs confirmation in a larger
group. More precise subtyping based on underlying disease mechanisms may allow more effective
targeting of treatment in IBS.
Trial registration: Current Controlled Trials ISRCTN76612274.
Funding: This project was funded by the Efficacy and Mechanism Evaluation (EME) programme, a MRC
and NIHR partnership.
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Plain English summary
I rritable bowel syndrome (IBS) is a chronic condition characterised by abdominal pain or discomfort andirregular bowel habit, which has many causes involving an interaction between the gut and brain. Mast
cells in the gut lining which can be activated by allergy or stress are thought to be important in causing
symptoms in some patients with IBS because they can release chemicals that cause pain and diarrhoea.
Currently, there are few effective treatments available to alleviate these symptoms. Recent small studies
have shown that mesalazine, an ‘anti-inflammatory’ drug, may be able to modify and reverse the
symptoms of IBS with diarrhoea. One small study suggested that mesalazine reduced mast cell numbers.
This current study is one of the largest studies looking at the use of mesalazine as a form of treatment for
IBS with diarrhoea. Unfortunately, this study did not show any beneficial effect of mesalazine treatment
in unselected patients with IBS and diarrhoea. Potentially, there is a subgroup of patients with IBS who
developed their symptoms following a bout of gastroenteritis and who appeared to benefit from
mesalazine treatment, but a larger study is needed to confirm this. We did not find that the mast cell
mediators released from mucosal biopsies were useful markers of disease, as they failed to correlate with
any symptoms.
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Scientific summary
Background
Irritable bowel syndrome (IBS) is a heterogeneous condition, characterised by abdominal pain/discomfort and
disturbed bowel habit. There is an interaction between gut pathology and disturbed central processing of
visceral afferent signalling in this group of patients. Patients may suffer from both diarrhoea (with accelerated
transit) and constipation (when transit is delayed), with around one-third of them having a mixed bowel
pattern with episodes of both diarrhoea and constipation. Both subtypes exhibit hypersensitivity to rectal
distension. Although the majority of patients with IBS have mild symptoms and are commonly managed in the
community, there is a small proportion of patients who have moderate to severe symptoms, who are referred
to secondary care for further investigations and management of their symptoms. Most treatments are based
on symptom control rather than a ‘cure’, owing to lack of understanding of the underlying mechanisms.
However, there have recently been reports of ‘immune activation’ in the mucosa of patients with
diarrhoea-predominant irritable bowel syndrome (IBS-D), such as increased mast cell numbers and release of
proinflammatory mediators, for example tryptase and histamine. This has been supported by animal studies
that clearly show mast cell activation by psychological stress, associated with the development of visceral
hypersensitivity, a key feature of IBS in humans. Although some reports have linked severity of pain to the
number of mast cells in close proximity to nerves, a link between symptoms and mast cell numbers or
mediators released from mucosal biopsies has not been seen in recent mechanistic studies. Other human
studies have reported increased in immune cells, such as T lymphocytes and enterochromaffin cells,
particularly in postinfectious IBS. There have been three small pilot randomised placebo-controlled trials and
one open-labelled study suggesting that mesalazine slow-release granule formulation (2 g; PENTASA®,
Ferring Pharmaceuticals Ltd), 5-aminosalicylic acid (5-ASA), may improve symptoms of IBS, such as abdominal
pain and improvement in bowel habit, particularly in patients with postinfective irritable bowel syndrome
(PI-IBS). One small study with just 20 patients showed a reduction in mast cell numbers following treatment.
Objectives
Our clinical primary outcome was to compare the effect of mesalazine with placebo on stool frequency.
Secondary clinical outcomes were to assess the effect of mesalazine on abdominal pain, stool consistency,
urgency and satisfactory relief of IBS symptoms. The primary mechanistic outcome was to assess change in
mast cell percentage area stained after treatment with mesalazine. Secondary mechanistic outcomes were
to assess mast cell tryptase release, volume of fasting small bowel water, faecal tryptase and calprotectin.
Methods
All participants met the modified Rome III criteria for IBS-D. Organic diseases were excluded with normal
blood tests and sigmoidoscopy/colonoscopy. Participants taking non-steroidal anti-inflammatory drugs
or 5-ASA compounds were excluded from the study. All participants were randomised after a 2-week
baseline stool diary. All participants completed a 12-week stool diary and at the end of each week
they recorded the presence of ‘satisfactory relief of IBS symptoms’.
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Results
Our large multicentred, parallel group, randomised placebo-controlled trial of mesalazine for treatment of
IBS-D, which randomised 136 subjects, was powered to detect a significant difference in bowel frequency
but has shown no clinical benefit over placebo in patients with IBS-D. Mechanistic assessments showed no
significant changes in mast cell numbers or mast cell mediators released from mucosal biopsies. We did
not find that the rate of release of mast cell products from a colonic biopsy was a useful biomarker, as it
failed to correlate with any symptoms. Mesalazine did not cause significant changes in fasting small bowel
water content, faecal tryptase or calprotectin. There was, however, a small number (n= 13) of patients
with IBS-D who met the criteria for PI-IBS and who showed significant clinical benefit of treatment with
mesalazine. This requires confirming in a further larger and more adequately powered study.
Conclusion
This study does not support any clinically meaningful benefit or harm of mesalazine compared with
placebo in unselected IBS with diarrhoea. If there is a subgroup that benefits it is likely to be those
with postinfective IBS and a trial of such patients, particularly those with more severe diarrhoea. Therefore,
a more precise subtyping based on underlying disease mechanisms is needed to allow more effective
targeting of treatment in IBS.
Trial registration
This trial is registered as ISRCTN76612274.
Funding
This project was funded by the Efficacy and Mechanism Evaluation (EME) Programme, a MRC and
NIHR partnership.
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Chapter 1 Background
Existing research
Irritable bowel syndrome (IBS) is one of the commonest conditions seen by gastroenterologists, experienced
by 1 in 10 of the population at some time in their lives and accounting for up to 40% of new referrals to
gastroenterology outpatients departments. The condition is characteristically heterogeneous but all patients
have abdominal discomfort and disturbed bowel habit.1 The other feature found in at least half of patients
with IBS is a history of anxiety or depression, and the presence of multiple unexplained physical symptoms,
otherwise known as ‘physical symptom disorder’ or ‘somatisation’, is present in two-thirds of patients.
Patients often believe that stress aggravates their symptoms but the effect does not appear to be
immediate, as there is a poor correlation between stress and symptoms on a day-to-day basis.2 The effect
appears to be more long term and patients with chronic stressors rarely recover until these are relieved.3 In
animals, chronic stress causes diarrhoea, an effect that appears to be mediated through the release of
corticotropin-releasing factor within the brain, where it activates descending autonomic pathways, delaying
gastric emptying and accelerating colonic transit. Corticotropin-releasing factor is also found locally in the
mucosa, where its release may activate mast cells. In addition to these effects of acute stress, chronic stress
in experimental animals, generated by repetitive water avoidance or lifelong stress following maternal
deprivation in the neonatal period, increases the number of mast cells within the mucosa. This leads to
increased gut permeability and increased translocation of bacteria with associated low-grade immune
activation within the mucosa.4
More recently, evidence has been accumulating that similar activation of mast cells can occur in stressed
humans. Acute stress induced by immersion of the hand into ice-cold water has been shown to stimulate
jejunal water secretion and the release of mast cell products, including tryptase and histamine, in healthy
volunteers (HVs).5 In patients with diarrhoea-predominant irritable bowel syndrome (IBS-D), mast cell numbers
have been shown to be increased in jejunal biopsies, along with intraepithelial CD3+ T lymphocytes (CD3).6
This study also showed higher tryptase concentration in aspirated jejunal fluid, suggesting that the mast cells
were activated,6 and more recent studies show that the ensuing increase in gut permeability is confined to
females, suggesting an important gender difference in susceptibility to stress-induced gut changes, which
accords with the known female predominance of IBS. We have recently confirmed increased numbers of mast
cells and intraepithelial lymphocytes in duodenal biopsies from patients with IBS-D in Nottingham, who also
show increased tryptase release into the supernatants of incubated duodenal biopsies.7
Importance of mast cells in generating irritable bowel
syndrome symptoms
There are numerous reports now of increased mast cell numbers in patients with IBS, in the terminal
ileum,8,9 caecum10 and rectum.11–13 Mast cells contain many mediators, including histamine, serotonin (5-HT)
and tryptase.14 Recent interest has focused on the tryptase content because it has been shown to activate
protease-activated receptor 2 (PAR2) receptors, which are found on afferent nerves, and their activation
increases sensitivity of the bowel to distension. Supernatants from IBS mucosal biopsies have been shown to
activate afferent nerves in an isolated mouse jejunal segment,15 and, more recently, in human colonic
submucosal nerves.14 We propose that anxiety and chronic stressors act in humans to increase the number
of activated mast cells throughout the gut in patients with IBS, thereby inducing the characteristic visceral
hypersensitivity and abdominal pain. We hypothesised that mesalazine slow-release granule formulation
(2 g; PENTASA®, Ferring Pharmaceuticals Ltd) treatment, through its anti-inflammatory effects, would
reduce the number of mast cells and thereby reduce abdominal pain, stool looseness and stool frequency.
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Previous studies of mast cell stabilisers and anti-inflammatory
agents in irritable bowel syndrome
Although there were some poorly designed trials two decades ago, claiming to show that sodium
cromoglycate was effective for IBS,16–18 these studies remain unconfirmed and the treatment is not widely
used. There have been other smaller studies targeting mast cells with antihistamines, such as ketotifen;19
although this reduced visceral hypersensitivity, it had no effect on mast cell numbers or release of mast cell
mediators. Our own trial of prednisolone in postinfective IBS (PI-IBS) was of limited duration – just 3 weeks –
and, although this showed a halving of CD3, patient symptoms were already subsiding and we were not
able to show any difference from the control subjects. In that study, the fall in mast cell numbers on
prednisolone was twice that on placebo but this difference was not statistically significant. We felt that
3 weeks was too short a time period to make an impact on mucosal histology. A strategy that reduced mast
cell numbers over the long term might well be more effective than specific inhibitors of mast cell activation,
or indeed any specific mast cell products, as these are numerous [histamine, tumor necrosis factor (TNF),
prostaglandin, substance P, mast cell tryptase and nerve growth factor (NGF)], all with quite variable
modes of action.
Previous studies of mesalazine treatment for irritable
bowel syndrome
The first anecdotal open-label trial of 12 patients with resistant IBS-D who responded to mesalazine20
showed a benefit that took about 2–3 months to become apparent. There have since been two further
reports of open-label treatment21,22 and two small randomised controlled trials.23,24 All but the Corinaldesi
et al.23 trial used patients with IBS-D. The Bafutto et al. trial22 used mesalazine 800mg three times a day for
30 days in 61 patients with IBS-D – 18 of whom had PI-IBS and showed benefit with a reduction in stool
frequency, stool consistency and abdominal pain – but was uncontrolled, with no placebo arm.
The Andrews et al. study21 involved just six patients but this showed that mesalazine decreased biopsy
proteolytic activity. Both of the randomised controlled trials23,24 are rather too small for their significance to
be sure, with n= 20 and n= 17, respectively. One study23 showed a significant reduction of mast cell
numbers and an overall reduction in inflammatory cells.
Risk and benefits
Mesalazine has been widely used for > 45 years and there are extensive data on its side effects. In general,
the drug is well tolerated. Nephrotoxicity is seen at a rate of about 1 per 100,000 prescriptions;25
commoner, but less serious, side effects include diarrhoea, nausea, vomiting and abdominal pain, together
with headaches, pancreatitis and blood disorders, which are all rare. Balancing this, patients with IBS suffer
a marked decrease in quality of life, similar to that of other chronic diseases such as diabetes and heart
failure. They also spend significant amounts of time off work and when they are at work they work less
efficiently. A simple safe and effective treatment would be of undoubted benefit to what is a substantial
subgroup of the population, given that IBS-D affects around 3% of the general population.
BACKGROUND
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Rationale for the current study
Studies in Nottingham over the last decade have identified the importance of inflammation in various
subgroups of IBS. We have focused on the group of patients with IBS who develop symptoms following
acute bacterial gastroenteritis, the so-called postinfectious IBS. In this group, we have been able to show
that the acute inflammatory insult associated with acute Campylobacter jejuni enteritis is followed by a
more prolonged indolent phase with increased chronic inflammatory cells long after the infecting organism
has left the body. In this subgroup of IBS we have demonstrated activated circulating peripheral blood
mononuclear cells with increased cytokine production and an associated increase in inflammatory gene
expression.26 We have also demonstrated the importance of anxiety and depression,27 which, along with
adverse life events, increase the risk of PI-IBS.28 The changes observed in PI-IBS are similar to those in IBS-D,
the predominant bowel disturbance being diarrhoea with a similar prognosis.29 This work has been
supported by others who have shown inflammatory changes in patients with IBS-D who do not have a
background of previous infection.30,31 Such studies have also shown increased inflammatory cells and
increased expression of inflammatory cytokines, including interleukin-1 beta (IL-1β).32 Increased gut
permeability has also been shown in IBS-D,33 making a trial of an anti-inflammatory treatment a logical
choice. Safety is of pre-eminent importance with IBS drugs, as can be seen by the recent withdrawal of
tegaserod34 (Zelnorm®, Novartis) and the previous withdrawal of alosetron (Lotronex®, Prometheus).35 Both
drugs, which were therapeutically effective, had to be withdrawn as a result of rare side effects (incidence
< 1 per 700 patients treated). This leaves such patients bereft of effective treatments, a gap that
mesalazine might well fill. Our hypothesis was that mesalazine, by virtue of its anti-inflammatory actions,
would alter the inflammatory mediators leading, over a number of weeks, to a reduction in the number
of mast cells and a reduction in the release of inflammatory mediators, and hence to a reduction in
symptoms. Previous studies have shown that 5-aminosalicylic acid (5-ASA) inhibits the release of
inflammatory mediators, including histamine and prostaglandin D2.36 It also inhibits activation of the
transcription factor ‘nuclear factor kappa-light-chain-enhancer’ of activated B cells, which is a major link in
the inflammatory cascade.37 More recently, it has been recognised that 5-ASA exerts an anti-inflammatory
effect that is mediated via peroxisome proliferator-activated receptor gamma (PPARγ receptors).38 Whether
directly or indirectly, 5-ASA has also been reported to inhibit inducible nitric oxide synthetase production
and also prostaglandin production via its cyclooxygenase-2 inhibitory effects.39 Mesalazine, therefore, both
by virtue of inhibiting other inflammatory pathways and by directly inhibiting mast cell pathways, may
reduce mucosal immune activation. We plan to investigate the effect of long-term mesalazine on mast cell
numbers, the chronic inflammatory cells and the mucosal production of inflammatory cytokines, IL-1β and
tumour necrosis factor alpha (TNF-α) as well as mast cell-specific tryptase. We also examined its effect on
stool calprotectin, a marker of colonic inflammation, which is widely used to exclude inflammatory bowel
disease and is also recognised to be modestly elevated in around 25% of most IBS series.
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Chapter 2 Trial/study purpose and objectives
Purpose
The purpose of the trial was to define the clinical benefit and possible mediators of the benefit of
mesalazine in IBS-D.
We therefore evaluated symptoms (primarily bowel frequency) and objective biomarkers reflecting mast cell
activation and small bowel tone.
Primary objective
Effect of mesalazine on stool frequency in weeks 11 and 12.
Secondary objectives
Effect of mesalazine on the following:
1. overall IBS symptoms
2. mast cell numbers, mucosal lymphocytes and faecal tryptases
3. small bowel tone by measurement of fasting small bowel water content through magnetic resonance
imaging (MRI).
Our overall aim was to assess the ability of the biomarkers listed above to predict treatment response.
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Chapter 3 Trial/study design
Trial/study configuration
This was a multicentre, two-arm, parallel-group, double-blind randomised placebo-controlled trial
comparing mesalazine with placebo in patients with IBS-D. The design of the study was modified after
consultation with a selection of interested patients from the Nottingham Digestive Diseases Biomedical
Research Unit patient advisory group, who provided a lay member for the Trial Steering Committee (TSC).
Randomisation and blinding
This was a double-blind, parallel-group study. The participant, supervising doctor and study nurse were not
aware of the treatment allocation.
The randomisation was based on a computer-generated pseudo-random code using random permuted
blocks of randomly varying size, created by the Nottingham Clinical Trials Unit (CTU) in accordance with
their standard operating procedure (SOP), and held on a secure server. The randomisation was stratified by
the recruiting centre. The supervising doctor or study nurse obtained a randomisation reference number
for each participant by means of a remote, internet-based randomisation system that was developed and
maintained by the Nottingham CTU.
The sequence and decode of treatment allocations were concealed until all interventions were assigned,
recruitment, data collection and all other trial-related assessments were complete, and data files
were locked.
Participants
Recruitment
Participants were recruited between April 2011 and May 2013, with the last patient completed in August
2013. Recruitment was from IBS clinics at the investigators’ hospital, or from lists of patients who had
previously taken part in research studies and had indicated that they would like to be contacted about
future relevant research projects. In addition, we had, in conjunction with the local Primary Care Research
Network (PCRN), approached general practitioners to ask them to search their databases for eligible
participants and send out letters of invitation along with participant information sheets (PISs). Either way,
the initial approach was from a member of the patient’s usual care team or from appropriately authorised
research nurses. We also advertised in the local newspaper. Initial recruitment into this trial was slow,
using the Rome III criteria1 based on daily diary recordings, whereas previous studies had used reported
symptoms based on recall. We felt that the eligibility criteria for IBS-D were too demanding. We therefore
modified the eligible criteria for IBS-D following registration with ‘ClinicalTrials.gov’ to reflect the fact that,
as others have found, the bowel habit of patients with IBS-D is less abnormal than patients’ reported
symptoms suggest.40
The patients were required to meet the modified Rome III criteria for IBS-D,1 defined as a stool frequency
of ≥ 3 per day for > 2 days per week and ≥ 25% of stools to be of types 5–7 [i.e. unlike standard Rome III
criteria,1 which state Bristol Stool Form Scale (BSFS) 6 and 7, to include stool form 5 as well] and < 25%
of types 1 and 2 according to the BSFS.41 To exclude other causes of diarrhoea, we required normal
colonoscopy and colonic biopsies, normal full blood count, serum calcium and albumin, C-reactive protein
and negative serological test for coeliac disease. Lactose intolerance was tested by asking patients to
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consume 568ml of milk per day and performing a lactose breath hydrogen test if they developed
diarrhoeal symptoms within 3 hours. If the stools were watery and frequent then the patient underwent a
7-day retention of selenium-75-labelled homocholic acid taurine test or a trial of cholestyramine to exclude
bile acid malabsorption. If any of these tests were positive then the patient was excluded from the study.
All patients gave written consent. Another inclusion criterion was age 18–75 years. Exclusion criteria
were prior history of major abdominal surgery; liver or kidney impairment; or chronic ingestion of any
anti-inflammatory drugs or medications that could affect the gut motility. All childbearing female patients
tested negative on the pregnancy test during the randomisation day and had to agree to adequate
contraception during the trial. Patients who were on long-term selective serotonin reuptake inhibitors
(SSRIs) or tricyclic antidepressants (TCAs) were included if they were on a stable dose for 3 months and
undertook to maintain the dose unaltered throughout the trial. During the screening period of 2 weeks,
patients were allowed a maximum of only two doses of 4mg loperamide (Immodium®, Janssen) per week
and discontinued any IBS medication. Once randomised, patients were allowed to take loperamide to
control their symptoms, as we hypothesised that mesalazine would take at least 6 weeks to exert its effect
on the gut. During the last 2 weeks of the trial when the primary end points were being assessed, patients
were not allowed loperamide or any antibiotics. Ethical approval was sought for any adverts or posters
displayed in the relevant clinical areas. Patients were seen in the research centres in participating hospitals
and enrolled by research nurses or doctors.
Patient visits and contacts are shown in Table 1.
Inclusion criteria
1. Male or female patients, aged 18–75 years, able to give informed consent.
2. Patients should all have had a colonoscopy or sigmoidoscopy within the last 12 months to exclude
microscopic or any inflammatory colitis (if not, but they have had a negative colonoscopy within 5 years
and symptoms are unchanged, then a sigmoidoscopy and mucosal biopsy of the left colon would be
sufficient to exclude microscopic or any inflammatory colitis).
3. Patients with IBS-D, meeting Rome III criteria1 prior to screening phase.
4. Patients with ≥ 25% soft stools (score > 4, i.e. 5–7) and < 25% hard stools (score 1 or 2) during the
screening phase, as scored by the daily symptom and stool diary.*
5. Patients with a stool frequency of ≥ 3 per day for ≥ 2 days per week during the screening phase.*
6. Satisfactory completion of the daily stool and symptom diary during the screening phase at the
discretion of the investigator.
7. Women of childbearing potential willing and able to use at least one highly effective contraceptive
method throughout the study. In the context of this study, an effective method is defined as those that
result in low failure rate (i.e. < 1% per year) when used consistently and correctly, such as implants,
injectables, combined oral contraceptives, sexual abstinence or vasectomised partner.
*If inclusion criterion 4 and/or 5 is/are not met but the results are considered atypical (as observed from
medical history and patient recall) then the patient can be rescreened on one occasion only. There must be
sufficient data completed during the screening phase to allow adequate classification.
Definition of diarrhoea-predominant irritable bowel syndrome meeting the
Rome III criteria
This was defined as abdominal pain or discomfort at least 2–3 days per month in the last 3 months
(criterion fulfilled for the last 3 months with symptom onset at least 6 months prior to screening)
associated with two or more of the following:
l improvement with defecation
l onset associated with a change of stool frequency
l onset associated with a change in form (appearance) of stool.
TRIAL/STUDY DESIGN
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Exclusion criteria
1. Women who are pregnant or breastfeeding.
2. Prior abdominal surgery that may cause bowel symptoms that are similar to IBS (note appendectomy
and cholecystectomy will not be exclusions).
3. Patients unable to stop antimuscarinic drugs, antispasmodic drugs, high-dose TCAs (i.e. > 50mg/day),
opiates/antidiarrhoeal drugs,* non-steroidal anti-inflammatory drugs (occasional over-the-counter use
and topical formulations are allowed), long-term antibiotic drugs, other anti-inflammatory drugs or
5-ASA-containing drugs.
4. Patients on SSRIs and low-dose TCAs (i.e. ≤ 50mg/day) for at least 3 months, previously unwilling to
remain on a stable dose for the duration of the trial.
5. Patients with other gastrointestinal diseases, including colitis and Crohn’s disease.
6. Patients with the following conditions: renal impairment, severe hepatic impairment or
salicylate hypersensitivity.
7. Patients currently participating in another trial or who have been involved in a trial within the previous
3 months.
8. Patients who in the opinion of the investigator are considered unsuitable owing to an inability to
comply with instructions.
9. Patients with serious concomitant diseases, for example cardiovascular, respiratory, neurological, etc.
(A full list of excluded or dose-controlled medications can be found in Appendix 1.)
*Loperamide is allowed as rescue medication throughout the trial; however, if > 2 doses per week are taken
during the screening phase then they are not eligible, although they can be rescreened on one occasion only.
Expected duration of participant participation
Study participants participated in the study for 14 weeks.
Removal of participants from therapy or assessments
The following subject withdrawal criteria applied:
1. Non-compliance – if < 75% of the investigational medicinal product (IMP) doses are taken between
visits, at the investigator’s discretion. (Dose as advised by the study doctor, taking into account that not
all participants will be advised to take the full study dose owing to intolerance.)
2. If the participant has remained on the initial lower dose of 2 g once a day for 3 weeks and the
medication is still not tolerated, at the investigator’s discretion.
3. Adverse reaction (serious and non-serious) with clear contraindications.
4. Participant withdraws consent.
5. Safety reasons, for example pregnancy.*
6. Lost to follow-up.
7. Participant develops an excluded/contraindicated condition.
8. Investigator discretion (e.g. protocol violations).
9. Unblinding, at the discretion of the principal investigator in conjunction with the chief investigator.
*In the event of a pregnancy occurring in a trial participant or the partner of a trial participant, monitoring
will occur during the pregnancy and after delivery to ascertain any trial-related adverse events (AEs) in the
mother or the offspring. When pregnancy occurs in the partner of a trial participant, consent will be
obtained for this observation from both the partner and her medical practitioner.
Participants withdrawn from the study were replaced. The participants were told that withdrawal would
not affect their future care. Participants were also made aware (via the information sheet and consent
form) that, should they withdraw, the data collected up to their withdrawal could not be erased and may
still be used in the final analysis.
TRIAL/STUDY DESIGN
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Chapter 4 Main outcome measures
Clinical outcomes
Primary outcome
1. Daily mean stool frequency during weeks 11–12 of the treatment period.
Secondary outcomes (all assessed during weeks 11–12 of the
treatment period)
1. Average daily severity of abdominal pain on a 0–10 scale.
2. Days with urgency during weeks 11–12 post randomisation.
3. Mean stool consistency using BSFS.
4. Global satisfaction with control of IBS symptoms, as assessed from the answer to the question
‘Have you had satisfactory relief of your IBS symptoms this week? Yes/no’.
Ancillary secondary end points
1. European Quality of Life-5 Dimensions (EQ-5D).
2. Centers for Disease Control and Prevention health-related quality of life Healthy Days Core Module
(CDC HRQOL4).
3. Hospital Anxiety and Depression Scale (HADS).
4. Patient Health Questionnaire 15 (PHQ-15).
Safety end points
1. AEs related to the trial treatment.
2. Withdrawal from the trial treatment as a result of AEs.
Mechanistic outcomes
Primary outcome
1. Mast cell numbers (mean percentage area stained) at week 12.
Secondary outcomes
1. Mast cell tryptase release during 6-hour biopsy incubation.
2. IL-1β, TNF-α, histamine and 5-HT secretion during same incubation.
3. Small bowel tone assessed by volume of fasting small bowel water.
4. Faecal tryptases and calprotectin.
5. Difference in primary outcome measure between those with different TNFSF15 polymorphism will be
assessed using analysis of variance (ANOVA).
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Chapter 5 Sample size
Our previous study on patients with IBS-D gives a mean stool frequency of 3.1 [standard deviation (SD)2.0]. Tuteja et al.24 reported mesalazine decreasing stool frequency by 1.4 bowel movements per day.
Our study had 80% power to detect such an effect at the 1% two-sided alpha level. We aimed to
randomise at least 125 patients to allow for 20% dropout rate but, owing to recruitment ongoing at
multiple sites and patient requests, we actually recruited 136.
Much smaller numbers are needed to assess the effect of mesalazine on mast cell numbers and tryptase
release. Corinaldesi et al.23 reported a 36% decrease in mast cell numbers from a mean of 9.2% over
lamina propria area, that is 2.96% over lamina propria area (SD 2.5% over lamina propria area), which,
assuming average change on placebo is 0, requires just 16 patients to show a significant difference with a
power of 90% at the 5% alpha level.
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Chapter 6 Data analysis
Analysis and presentation of data was in accordance with Consolidated Standards of Reporting Trials(CONSORT) guidance. The primary data set included stool diary filled for at least 10 days out of 14.
Balance between the trial arms at baseline was examined using appropriate descriptive statistics. For
continuous variables, data were summarised in terms of the mean, SD, median, lower and upper quartiles,
minimum, maximum and number of observations. Categorical variables were summarised in terms of
frequency counts and percentages.
The general approach for between-group comparisons was intention to treat (ITT). Appropriate regression
modelling was used to evaluate the primary and secondary outcomes, and safety data, with due emphasis
placed on clinical importance of 95% confidence intervals (CIs) for between-group estimates.
No formal adjustment for multiple significance testing was applied. We also performed a sensitivity analysis
using multiple imputation of missing data for the primary outcome.
Full details were given in a separate Statistical Analysis Plan approved before data lock.
The safety monitoring functions of the trial was undertaken by the Data Monitoring and Ethics
Committee (DMEC).
Assessment of efficacy
We used descriptive statistics to compare the randomised groups at baseline. The primary outcome was
assessed using ITT without imputation. We used a generalised linear mixed model to compare the
mesalazine group and placebo group for the primary outcome, with adjustment for the baseline value of
the outcome, and study centre as a random effect. Additionally, we adjusted for any variables showing
imbalance at baseline in secondary models. We compared the characteristics of participants who did and
did not adhere with the study medication before estimating the treatment effect if the medication was
actually taken using Complier Average Causal Effect (CACE) analysis. We investigated the effect of missing
primary outcome data using multiple imputation. The secondary outcomes were assessed using similar
models as for primary outcome, or logistic or Poisson regression, as appropriate, dependent on
outcome type.
We undertook subgroup analyses by including appropriate interaction terms in the linear mixed model for
primary outcome according to baseline daily mean stool frequency, baseline mean abdominal pain score
and baseline mean HADS anxiety score.
Secondary outcomes were treated similarly, after transformation if appropriate, whereas binary and count
outcomes were handled by multiple logistic or Poisson regression, as appropriate. Given the large number
of potential comparisons, p-values for mechanistic variables will not be presented. All analyses were
performed using Stata version 13 (StataCorp LP, College Station, TX, USA) adopting the ITT principle
without imputation for missing data (with a sensitivity analysis using multiple imputation for the
primary outcome).
We planned to conduct a number of prespecified subgroup analyses.
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For each of the three outcomes listed below, we investigated whether or not there were any differences in
between-group effects according to the following baseline variables: anxiety, stool frequency, abdominal
pain and mast cell activation:*
1. stool frequency during weeks 11–12
2. number of days with any stool consistency scoring 6 or 7 during weeks 11–12
3. mean score of worst pain for each day, averaged over weeks 11 and 12.
*Mast cell activation will be defined as elevation of any of the inflammatory mediator components, such as
mast cell tryptase, IL-1β, TNF-α, histamine and 5-HT in biopsy supernatant.
These subgroup analyses were conducted by including appropriate interaction terms in the regression
models and, as the study has not been powered to detect any such subgroup effects, were considered as
exploratory and would require confirmation in future research.
The primary mechanism hypothesis to be investigated was that treatment with mesalazine reduces
inflammation, which, in turn, reduces clinical symptoms. The aim of this type of analysis is to estimate how
much of any observed treatment effect can be attributed to a variable that is thought to be an intermediate
on the causal pathway, or mediator.
After summarising inflammatory markers at baseline and 11–12 weeks’ follow-up by trial arm using
appropriate descriptive statistics, we will examine change in these markers (stool calprotectin, mast cell
tryptase, mast cell percentage area stained) and change in stool frequency using a scatter plot.
Definition of populations analysed
Safety set All randomised participants who receive at least one dose of the study drug. All AEs in this set
are reported.
ITT set All randomised participants for whom at least one post-baseline assessment of the primary end
point is available.
Stool samples and sigmoid colon biopsies
These were collected at week 0 and the end of trial (EOT) from patients recruited in Nottingham. Stools
collected were analysed for calprotectin. A commercially available calprotectin enzyme-linked
immunosorbent assay (ELISA) kit (Buhlmann, Schönenbuch, Switzerland) was used for extraction and
quantification of stool calprotectin. Samples were analysed for faecal tryptase based on a method
published recently by our group.42 Faecal protease activity is expressed in trypsin units per mg of protein.
DATA ANALYSIS
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Sigmoid biopsies were collected for immunohistochemistry for mast cell tryptase, CD3, CD68 (a marker of
macrophage) and 5-HT, and tissues were processed and stained in the histopathology laboratory in
Nottingham University Hospitals NHS Trust, UK. A further set of biopsies was maintained in culture and
supernatants collected were assayed for (1) mast cell tryptase, chymase, carboxypeptidase A3 (CPA3) and
histamine, and (2) IL-1β and TNF-α levels. The biopsy tissues were incubated immediately in Hanks’
medium for 30 minutes before storing at –80 °C until assays for (1) mast cell mediators were performed by
the Immunopharmacology Group at the University of Southampton; and (2) IL-1β and TNF-α levels were
performed by RI, Research Fellow in Centre of Biomolecular Science, University of Nottingham. Levels of
IL-1β and TNF-α was analysed by using a commercial kit V-PLEX immunoassay (Meso Scale Discovery,
Rockville, MD, USA).
Histological methods (see Appendix 2)
Mast cell numbers were assessed as the mean of area percentage stained per region of interest (m2).
Faecal tryptase
Stool samples were collected at baseline (randomisation day) and at the EOT (end of week 12).
DOI: 10.3310/eme02020 EFFICACY AND MECHANISM EVALUATION 2015 VOL. 2 NO. 2
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Lam et al. under the terms of a commissioning contract issued by the Secretary of State for Health.
This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that
suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR
Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton
SO16 7NS, UK.
17

Chapter 7 Results
O f 221 patients initially screened, 185 were eligible and 136 were enrolled and randomised into thestudy (Figure 1). Follow-up was completed in August 2013. The most frequent reason for exclusion
was disinclination to participate. The commonest reason for not meeting inclusion criteria was that the
patients’ diaries during the 2 weeks’ run-in period indicated that they did not have loose stools ≥ 25% of
the time or stool frequency of ≥ 3 per day for ≥ 2 days per week.
Demographics
A total of eight sites participated in this study. Table 2 and Appendix 2 (see Table 16) show a summary of
recruitment by site and by treatment arm.
Characteristics of enrolled patients in both groups were similar at baseline (Table 3).
Primary and secondary outcome data were collected for 115 (85%) and 116 (85%) participants,
respectively, at 11–12 weeks of follow-up.
Number of patients screened
(n = 221)
Randomised (n = 136)
Allocated to IMP (n = 68) Allocated to placebo (n = 68) 
Primary outcome not available (n = 11)
• Withdrew consent, n = 2
• Lost to follow-up, n = 1
• AE, n = 8
Pregnant, n = 1
Dizzy, n = 1
Discoloured urine, n = 1
Exacerbation of IBS, n = 2
Chest pain, n = 1
Breast cancer, n = 1
Flu-like illness, n = 1
Primary outcome not available (n = 10)
• Withdrew consent, n = 2
• Lost to follow-up, n = 1
• Incomplete diary weeks 11−12, n = 1
• AE, n = 6
Included in ITT analysis (n = 57) Included in ITT analysis (n = 58)
Excluded (n = 85)
• Not meeting inclusion criteria, n = 36
• Declined to participate, n = 49
 Bloating, n = 2
 Exacerbation of IBS, n = 3
 Rash, n = 1
FIGURE 1 Patient flow chart (CONSORT diagram).
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Clinical primary outcome
The primary ITT comparison showed no evidence of any clinically significant difference between mesalazine
and placebo for the primary outcome (Table 4). Additional adjustments for variables (age, abdominal pain
score, number of days with urgency and PHQ-15 score) displaying imbalance at baseline did not materially
change the results (Table 5a) and nor did multiple imputation analysis or CACE analysis (Table 5b–c).
Subgroup analyses (Table 6a) of the primary outcome by baseline daily mean stool frequency suggest
that mesalazine may be more effective among patients with greater baseline stool frequency and is
associated with larger treatment effect, but this could be a chance finding and would require confirmation
in further studies. There was no evidence that treatment effect differed according to baseline pain or
HADS (Table 6b and c). Our sensitivity analysis, using multiple imputation of missing data for the primary
outcome, showed no effect on primary outcome (see Table 6b).
TABLE 2 Summary of recruitment by site and by treatment arm
Site Placebo, n Mesalazine, n
Nottingham 38 40
Manchester 16 15
Derby 2 2
Mansfield 4 3
Doncaster 5 5
Stoke-on-Trent 1 1
South Tees 1 1
North Tees 1 1
TABLE 3 Summary of baseline data by treatment group
Characteristic Mesalazine (n= 68) Placebo (n= 68) Total (n= 136)
Age at enrolment (years), mean (SD) 42.6 (15.2) 47.1 (13.5) 44.8 (14.4)
Gender, (male), n (%) 26 (38.2) 28 (41.2) 54 (39.7)
Ethnicity, n (%)
White 66 (97.1) 66 (97.1) 132 (97.1)
Black 0 1 (1.5) 1 (0.7)
Asian 1 (1.5) 0 1 (0.7)
Mixed 1 (1.5) 0 1 (0.7)
Other 0 1 (1.5) 1 (0.7)
Daily mean stool frequency, mean (SD) 3.6 (1.6) 3.6 (1.8) 3.6 (1.7)
Daily mean abdominal pain score, mean (SD) 4.1 (2.2) 3.6 (2.0) 3.6 (1.7)
Number of days with urgency, median (IQR) 13 (10–14) 12 (9–14) 12.5 (9–14)
Stool consistency, mean (SD) 5.4 (0.7) 5.6 (1.0) 5.5 (4.4)
HADS score, mean (SD) 9.1 (4.5) 8.6 (4.3) 8.8 (4.4)
PHQ-15 score, mean (SD) 12.6 (5.2) 13.1 (5.6) 12.8 (5.4)
IQR, interquartile range.
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TABLE 4 Clinical primary outcome of daily mean stool frequency at weeks 11–12
Group/comparison
Daily mean stool frequency at
11–12 weeks, mean (SD)
Between-group difference at
11–12 weeks (95% CI) p-value
Placebo 2.7 (1.9) (n= 58) – –
Mesalazine 2.8 (1.2) (n= 57) – –
Mesalazine vs. placebo – 0.10 (–0.33 to 0.53) 0.658
TABLE 5a Primary analysis of average stool frequency with further adjustment of baseline covariates
Comparison Adjusteda difference in mean frequency p-value 95% CI
Mesalazine vs. placebo 0.13 0.562 –0.31 to 0.57
a Adjusted by age, study centre and baseline daily mean stool frequency.
TABLE 5b Primary analysis of average stool frequency with multiple imputation
Comparison Adjusteda difference in mean frequency p-value 95% CI
Mesalazine vs. placebo 0.06 0.172 –0.18 to 0.99
a Adjusted by baseline daily mean stool frequency and study centre.
TABLE 5c Primary analysis of average stool frequency (CACE)
Comparison Adjusteda difference in mean frequency p-value 95% CI
Mesalazine vs. placebo 0.16 0.669 –0.58 to 0.91
a Adjusted by baseline daily mean stool frequency and study centre.
TABLE 6a Primary outcome subgroup analysis by baseline stool frequency
Baseline frequency Placebo (n= 58) Mesalazine (n= 57)
Daily mean stool frequency at 11–12 weeks by baseline frequency, mean (SD)
≤ 2.4 1.6 (0.5) 1.7 (0.4)
> 2.4 and ≤ 3.4 2.2 (1.1) 2.2 (0.5)
> 3.4 and ≤ 4.6 2.7 (0.9) 3.1 (1.3)
> 4.6 4.7 (2.9) 4.1 (1.1)
Estimatesa for interaction in primary analysis model with 95% CI and p-value
Primary outcome by baseline stool frequency –0.26 (–0.51 to –0.01); p= 0.043
a Adjusted by baseline daily mean stool frequency and study centre.
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Clinical secondary outcomes
No differences were apparent for any of the secondary outcomes, with the exception of number of days
with urgency (Table 7), which were increased by about 20% on mesalazine treatment compared
with placebo.
Compliance
Compliance was defined a priori as taking ≥ 75% of the medication throughout the 12 weeks. Each
patient was given two boxes of medication during the 12-week study, each box containing 100 sachets.
The amount of medication taken was calculated by 200 minus the number of medication sachets returned
at EOT. Compliance with medication (Table 8) and baseline characteristics of compliers (defined as taking
≥ 75% of the medication throughout the 12 weeks) were similar in both groups. Analysis of the primary
outcome using the CACE approach showed no difference between the two treatment arms (mean
difference 0.2, 95% CI –0.6 to 0.9).
TABLE 6b Primary outcome subgroup analysis by baseline abdominal pain score
Baseline pain score Placebo (n= 58) Mesalazine (n= 57)
Daily mean stool frequency at 11–12 weeks by baseline abdominal pain score, mean (SD)
≤ 2.2 2.9 (2.8) 2.7 (0.9)
> 2.2 and ≤ 4.1 2.6 (1.4) 2.4 (0.7)
> 4.1 and ≤ 5.3 2.4 (1.4) 3.0 (1.6)
> 5.3 3.2 (1.7) 2.9 (1.3)
Estimatesa for interaction in primary analysis model with 95% CI and p-value
Primary outcome by baseline pain score –0.03 (–0.10 to 0.04); p= 0.361
a Adjusted by baseline daily mean stool frequency and study centre.
TABLE 6c Primary outcome subgroup analysis by baseline HADS score
Baseline HADS score Placebo (n= 58) Mesalazine (n= 57)
Daily mean stool frequency at 11–12 weeks by baseline HADS score, mean (SD)
≤ 5.0 3.1 (3.2) 3.0 (1.4)
> 5.0 and ≤ 9.0 2.3 (1.3) 2.8 (1.2)
> 9.0 and ≤ 11.5 3.0 (1.5) 2.9 (1.3)
> 11.5 2.0 (0.9) 2.6 (1.3)
Estimatesa for interaction in primary analysis model with 95% CI and p-value
Primary outcome by baseline HADS score –0.01 (–0.04 to 0.03); p= 0.792
a Adjusted by baseline daily mean stool frequency and study centre.
RESULTS
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TABLE 7 Secondary outcome results
Treatment outcome with
mesalazine or placebo Baseline 11–12 weeks
Between-group comparison
at 11–12 weeks (95% CI)a p-value
Daily mean abdominal pain score,
mean (SD)
Placebo 3.6 (2.0) 2.2 (2.1) (n= 59) – –
Mesalazine 4.1 (2.2) 2.8 (2.1) (n= 57) – –
Mesalazine vs. placebo – – 0.07 (–0.54 to 0.68)b 0.828
Number of days with urgency,
median (IQR)
Placebo 12 (9–14) 8 (1–13) (n= 59) – –
Mesalazine 13 (10–14) 11 (5–14) (n= 57) – –
Mesalazine vs. placebo – – 1.22 (1.07 to 1.39)c 0.003
Weekly mean stool consistency,
mean (SD)
Placebo 5.6 (1.0) 4.7 (1.1) (n= 59) – –
Mesalazine 5.4 (0.7) 4.7 (1.0) (n= 57) – –
Mesalazine vs. placebo – – 0.13 (–0.21 to 0.48)b 0.452
Number of days with consistency
score 6 or 7, median (IQR)
Placebo 11 (8–13) 6 (2–9) (n= 59) – –
Mesalazine 11 (8–13) 7 (2–11) (n= 57) – –
Mesalazine vs. placebo – – 1.09 (0.95 to 1.27)c 0.210
Mean HADS score
Placebo 8.6 (4.3) 6.9 (3.6) (n= 59) – –
Mesalazine 9.0 (4.5) 7.5 (5.0) (n= 57) – –
Mesalazine vs. placebo – – 0.67 (–0.38 to 1.72)b 0.210
Mean PHQ-15 score, mean (SD)
Placebo 13.1 (5.6) 9.4 (5.0) (n= 59) – –
Mesalazine 12.6 (5.2) 10.0 (5.2) (n= 57) – –
Mesalazine vs. placebo – – 0.63 (–0.93 to 2.20)b 0.428
Number of people with satisfactory
relief of IBS symptoms, n (%)
Placebo 0 24 (40.7) (n= 59) – –
Mesalazine 0 25 (43.9) (n= 57) – –
Mesalazine vs. placebo – – 1.13 (0.51 to 2.47)d 0.762
continued
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EQ-5D: five division components
that have no problems, n (%)
Baseline After treatment
Placebo Mesalazine Placebo Mesalazine
Mobility 46 (67.6) 53 (77.9) 47 (79.3) 44 (77.2)
Self-care 66 (97.1) 63 (92.6) 57 (96.6) 52 (91.2)
Usual activity 39 (57.4) 44 (64.7) 44 (74.6) 45 (78.9)
Pain/discomfort 7 (10.3) 8 (11.8) 15 (25.4) 15 (26.3)
Anxiety/depression 39 (57.4) 39 (57.4) 37 (62.7) 35 (61.4)
EQ VAS score, mean (SD) Baseline After treatment
Between-group comparison
(95% CI) p-value
Placebo 64.3 (20.2) 69.7 (18.3) (n=59) – –
Mesalazine 64.2 (20.6) 72.6 (19.2) (n=57) – –
Mesalazine vs. placebo – – 2.39 (–3.24 to 8.02)b 0.406
EQ VAS, EuroQol visual analogue scale; IQR, interquartile range.
a Estimate depends on type of outcome variable and is adjusted by baseline value of the outcomes if appropriate.
b Difference in means.
c Incidence rate ratio.
d Odds ratio.
TABLE 8 Summary of compliance with trial medication (participants who completed 12 weeks of treatment)
Compliance with medication Placebo (n= 59) Mesalazine (n= 57)
Compliance,a mean (SD) % 72 (17) 71 (19)
Complier,b n (%) 35 (59) 33 (58)
a Calculated as 100 minus the proportion of trial medication returned.
b Complier is defined as compliance ≥ 75%.
TABLE 7 Secondary outcome results (continued)
RESULTS
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Adverse events
The most frequently occurring side effect was exacerbation of IBS symptoms, which could be worsening
abdominal pain or diarrhoea. Two patients (3%) from the mesalazine group and three (5%) from the
placebo group complained of this and were withdrawn from the study. Other less frequent side effects are
listed in Appendix 2 (see Table 15). One patient was pregnant in the middle of the trial period, although
she had a negative result in a pregnancy test at the start of the trial. She was withdrawn from study with
no adverse consequence to her or her newborn.43 One patient from the mesalazine group was found to
have breast cancer and she was withdrawn from the study, as her IBS symptoms and stool diary would
have been very difficult to interpret. All participants who developed these AEs were withdrawn from the
study and their symptoms settled on follow-up – see Appendix 2, Table 15.
Mechanistic primary outcome
Mast cells
The mast cell percentage area stained was not elevated in patients with IBS-D compared with our normal
range that was established previously in our laboratory. The baseline mast cell percentage area stained
for patients with IBS-D was median 2.25% [interquartile range (IQR) 1.86–2.73%], compared with median
2.42% (IQR 2.09–3.39%) in the healthy control subjects (Figure 2). There was no reduction in mast cell
percentage area stained following treatment with mesalazine (Figure 3 and Table 9).
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FIGURE 2 Mast cell count assessed from percentage area stained comparing healthy control subjects and patients
with IBS-D (median, IQR).
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FIGURE 3 Effect of mesalazine vs. placebo on mast cell percentage area stained in patients with IBS-D
(median, IQR).
TABLE 9 Effect of mesalazine vs. placebo on mast cell percentage area stained/m2 in patients with IBS-D
[median (IQR)]
Mesalazine Placebo
Baseline After treatment Baseline After treatment
2.11 (1.06–2.11) 2.29 (1.86–2.75) 2.33 (1.88–2.74) 2.25 (1.5–2.59)
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Mechanistic secondary outcome
Mast cell tryptase and other mediator release during biopsy incubation
Baseline supernatant levels were compared between patients with IBS-D and our normal range in healthy
volunteers. There was no significant increase in the baseline mediator levels except CPA3 (Figure 4 and
Table 10).
Following treatment with either mesalazine or placebo in the patients with IBS-D, there was no change in
the supernatant levels of the mediators (Table 11 and Figures 5–9).
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FIGURE 4 Baseline CPA3 levels in patients with IBS-D. Shaded area indicates normal range in HVs (median, IQR).
TABLE 11 Supernatant mediator levels (ng/ml) following treatment with mesalazine or placebo [median (IQR)]
Supernatant mediators
Mesalazine
baseline (n= 21)
Placebo
baseline (n= 23)
Mesalazine
after treatment
Placebo after
treatment
Tryptase 4.3 (1.5–8.6) 4.6 (2.5–9.1) 4.9 (1.8–8.2) 5.8 (2.1–10.3)
Chymase 0 (0–0.3) 0 (0–0.8) 0 (0–1.7) 0 (0–0.4)
CPA3 0 (0–0.3) 0 (0–1.0) 0 (0–0.8) 0 (0–0.5)
Histamine 0.9 (0.3–1.4) 0.7 (0–1.4) 0.8 (0–1.2) 0.7 (0.2–1.0)
5-HT 9.4 (6.1–15.1) 6.3 (2.7–13.7) 10.7 (5.4–14.0) 9.3 (3.4–14.7)
TABLE 10 Baseline supernatant levels (ng/ml) between HVs and patients with IBS-D [median (IQR)]
Mediator HVs, n= 21 IBS-D patients, n= 45 p-value
Tryptase 6.7 (3.8–11.4) 4.3 (1.8–8.9) 0.07
Chymase 0 0 (0–0.9) 0.14
CPA3 0.34 (0.28–0.52) 0 (0–0.9) 0.0496
Histamine 1.6 (0.7–3.8) 0.7 (0–1.3) < 0.01
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FIGURE 5 Tryptase levels before and after treatment with mesalazine or placebo (median, IQR).
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FIGURE 6 Chymase levels before and after treatment with mesalazine or placebo (median, IQR).
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FIGURE 7 Carboxypeptidase A3 levels before and after treatment with mesalazine or placebo (median, IQR).
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FIGURE 8 Histamine levels before and after treatment with mesalazine or placebo (median, IQR).
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Interleukin-1 beta, tumour necrosis factor alpha
Levels of IL-1β and TNF-α in supernatant were below the level of detection.
Small bowel tone assessed by volume of fasting small bowel water
Fasting small bowel water showed wide variability, ranging from 5 to 220ml. This did not alter significantly
after treatment with either mesalazine or placebo (Table 12, Figures 10 and 11).
Faecal tryptases
Totals of 27 and 30 pairs of stool samples were collected in the mesalazine and placebo groups,
respectively. The baseline faecal tryptase level was in the range of between 6.8 and 577.8 trypsin units/mg
of protein, which was highly variable. There was a significant increase in faecal tryptase after treatment
with mesalazine (Table 13 and Figure 12). There was no correlation between baseline faecal tryptase level
and baseline supernatant tryptase level: Spearman’s r= 0.13, p= 0.41. There was no significant correlation
between baseline faecal tryptase level and anxiety, depression or bowel symptoms.
Difference in primary outcome measure between those with different
TNFSF15 polymorphism
Genotyping has yet to be done but, given the predicted small numbers with the risk allele and the lack of
evidence of immune activation, a significant gene effect is unlikely to be detected.
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FIGURE 9 Serotonin levels before and after treatment with mesalazine or placebo (median, IQR).
TABLE 12 Fasting small bowel water content (ml) following treatment with either mesalazine or placebo
Fasting small bowel water content (ml), median (IQR)
Mesalazine baseline (n= 17) Placebo baseline (n= 20) Mesalazine after treatment Placebo after treatment
58 (27–122) 58 (28–106) 48 (36–79) 58 (21–96)
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FIGURE 10 Fasting small bowel water before and after treatment with mesalazine or placebo (median, IQR).
Mesalazine Placebo
0
50
100
 F
as
ti
n
g
 s
m
al
l b
o
w
el
 w
at
er
 (
m
l)
Baseline
After treatment
150
200
250
FIGURE 11 Changes in fasting small bowel water before and after treatment with either mesalazine or placebo.
TABLE 13 Faecal tryptase levels (trypsin units/mg protein) following treatment with mesalazine or placebo
Baseline, median (IQR) After treatment, median (IQR)
Mesalazine (n= 30) Placebo (n= 27) Mesalazine Placebo
61.2 (37.6–101.4) 66.5 (44.8–126.5) 82.7 (40.5–194.8) 70.9 (36.0–191)
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Post hoc analysis
Mast cell percentage area stained
There was no correlation between mast cell percentage area stained with clinical features, such as
abdominal pain severity, urgency, bloating, daily mean stool frequency or stool consistency.
We found no significant correlation of mast cell percentage area stained with objective measures of
tryptase, chymase, CPA3 and histamine in biopsy supernatants.
Other immune cells, for example CD3+ T lymphocyte, CD68- and
serotonin-containing enterochromaffin cells
There was no effect on either treatment with mesalazine or placebo on CD68-staining macrophages or
on 5-HT-containing enterochromaffin cells. There was a paradoxical increase in CD3 count following
treatment with mesalazine for reasons which are unclear (Figure 13).
Stool calprotectin
Samples were obtained from 53 patients (30 placebo group, 23 mesalazine group). Baseline stool
calprotectin levels varied widely, ranging from undetectable to as high as 420 µg/g. There was a negative
correlation between calprotectin levels and baseline total HADS score but this did not reach significance
(r= 0.25, p= 0.07) (Figure 14).
When patients were divided into two groups based on stool calprotectin levels of ≤ 100 µg/g (group B) and
≥ 101 µg/g (group A), the group with higher calprotectin levels (≥ 101 µg/g, group A) at baseline showed
a significantly lower total HADS score than the normal calprotectin level group (group B) (Figure 15).
Otherwise, comparing these two groups, there were no differences with their baseline clinical
characteristics such as abdominal pain severity, average daily stool frequency and stool consistency.
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FIGURE 12 Change in faecal tryptase following treatment with mesalazine compared with placebo (median, IQR).
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FIGURE 13 CD3+ T lymphocyte count before and after treatment with mesalazine or placebo (median, IQR).
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FIGURE 14 Correlation between baseline calprotectin levels (µg/g) and baseline total HADS score.
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Postinfectious irritable bowel syndrome
Thirteen participants met the previously published criteria for PI-IBS.11 They had to meet Rome III criteria1
for IBS following an episode of infectious gastroenteritis characterised by ≥ 2 of the following symptoms:
fever, vomiting, diarrhoea and positive stool culture.11 Eight participants were randomised into the
mesalazine group and five were allocated to the placebo group. There was significant improvement in
clinical symptoms – such as abdominal pain, urgency and stool consistency – following treatment with
mesalazine but not with placebo (Figures 16–18).
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FIGURE 15 Baseline stool calprotectin levels when divided into two groups (median, IQR).
Mesalazine group Placebo group
10
8
6
4
2
0
Li
ke
rt
 s
ca
le
Baseline
After treatment
FIGURE 16 Abdominal pain severity before and after treatment with mesalazine or placebo.
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FIGURE 17 Urgency symptoms before and after treatment with mesalazine or placebo.
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FIGURE 18 Stool consistency before and after treatment with mesalazine or placebo.
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Chapter 8 Discussion
Over the past decade, there have been several promising studies using 5-ASA for treatment of bothIBS-D23,44 and PI-IBS45,46 but sample sizes were small and their significance was uncertain. These studies
were motivated by recent findings of ‘immune activation’ in the gut mucosa of patients with IBS,
dominated by mast cells and T lymphocytes rather than the polymorphonuclear leucocytes that are
characteristic of colitis. These studies were supported by several studies suggesting impaired mucosal
barrier in IBS,47 which, by allowing access of luminal bacterial products to the mucosal immunocytes, might
cause this activation.48 These data suggested that mesalazine, being an anti-inflammatory agent, might
benefit this condition. Our study is one of the largest trials so far looking at the treatment of patients with
IBS-D with mesalazine following best practice to ensure that both investigators and patients were blinded
to the study and that data analysis was carried out by independent statisticians. We analysed the effect of
mesalazine only after 12-week treatment, as we felt that mesalazine was a disease-modifying treatment
rather than a symptomatic treatment, and early reports suggested that benefit was most obvious after
2–3 months.20 Our study showed that mesalazine did not improve bowel frequency after 12 weeks’
treatment when compared with placebo in unselected patients. As with other studies of IBS, we found a
strong placebo effect on bowel symptoms and also on the total HADS and somatic scores, suggesting that
patients felt better, in general, after taking part in the trial.
Despite lack of benefit in unselected patients, we had preplanned subanalysis of the primary outcome of stool
frequency in patients who were divided according to severity. This suggested that a group of patients who had
the greatest bowel frequency did show a small benefit from mesalazine (mean difference –0.26, p= 0.04). Our
clinical findings seem consistent with another recent report.49 There was no significant improvement, however,
in other IBS symptoms, such as abdominal pain, bloating and stool consistency. There is strong evidence from
our study that mesalazine treatment increases the number of days with urgency by about 20%. There have
been previous case studies reporting treatment with mesalazine worsening diarrhoea in colitis.50,51 This may
represent an allergic response to the drug, as we did find an increase in T lymphocytes.
Raised mast cells numbers in the gut mucosa have been implicated in all subtypes of IBS,52 but mainly in
IBS-D. Mast cells contain many mediators, including histamine, 5-HT and proteases such as tryptase.14
Recently, there has been focus of interest on tryptase content, as it has been shown to activate PAR-2,
which is found on afferent nerves and can lead to increased sensitivity of bowel distension.53 In our study,
the mast cell percentage area stained in patients with IBS-D was not elevated, compared with that in our
previously studied healthy subjects. Despite our large numbers we were able neither to confirm the gender
difference in mast cell count of patients with IBS-D, as previously described by others,54 nor find any
gender effect on other immune cells such as CD3-, CD68- and 5-HT-containing enterochromaffin cells.
Similarly, the supernatant levels of tryptase in patients with IBS-D were not significantly elevated, compared
with healthy control subjects. Median (IQR) tryptase levels for IBS-D compared with healthy control subjects
were 4.3 (1.8–8.9) ng/ml and 6.7 (3.8–11.4) ng/ml; p= 0.07. We were not, therefore, able to confirm
either increased mast cell numbers or increased mast cell tryptase release from biopsies, as some,14,15
but not all,19 investigators have found. Our study provides no support for the previous suggestion that
mesalazine can reduce mast cell numbers.23
Surprisingly, supernatant histamine levels in our study were lower in patients with IBS-D than in healthy
control subjects [mean 0.7 (SD 0.6) and mean 1.1 (SD 0.8) ng/ml, respectively; p= 0.02]. Supernatant levels
of tryptase and histamine were not altered following treatment with mesalazine. Disappointingly, we
found no apparent association correlation between mast cell percentage area stained and supernatant
levels of release of the mast cell mediators examined, whether those released by all mast cells (tryptase,
histamine) or those restricted to a subpopulation (chymase, CPA3). This suggests that the overall degree of
mediator release from colonic mast cells is independent of mast cell numbers, suggesting that factors other
than mere numbers determine mediator release.
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Stool collected in Nottingham was used to obtain calprotectin level at baseline and EOT. Although a small
proportion of patients had raised calprotectin levels (≥ 100 µg/g), we had excluded organic diseases – such
as inflammatory bowel disease – in gastroenterology clinics using standard tests prior to the patients
entering the study. Others have also reported that up to one-quarter of patients with IBS have marginally
elevated calprotectin levels, although the origin of this is unclear.55,56 Interestingly, the subgroup of patients
(group A) who had raised calprotectin levels (≥ 101 µg/g) have significantly less psychological distress than
the group with stool calprotectin level of ≤ 100 µg/g (group B). We speculate that subgroup A symptoms
are secondary to local gut inflammation, whereas subgroup B symptoms are driven primarily by distress,
which causes gut symptoms secondarily. Unfortunately, numbers were too small to answer the question of
whether or not subgroup A responded better to mesalazine. Stool calprotectin could, therefore, be used as
a screening tool to allow more detailed studies of the mucosa in IBS-D in the future.
One uncontrolled study45 has suggested that mesalazine might be effective in treating patients with PI-IBS,
but the only randomised controlled trial of mesalazine in this condition was negative, although possibly
underpowered.46 In our post hoc analysis, a small subgroup fulfilling criteria for PI-IBS appeared to benefit
from mesalazine, but our study was also underpowered. Confirming this would require a larger and more
adequately powered study.
Although mesalazine has been available to use for many decades with a good safety profile, our
adequately powered study has shown that it does not help the majority of patients with IBS-D. The fact
that certain subgroups might benefit emphasises that there is still a need for better phenotyping of this
heterogeneous group of patients when evaluating new treatments.
Limitations
Despite strict entry criteria, our population was still heterogeneous. In retrospect, it would have been
better if we had stratified by postinfectious onset. We did consider this but felt that this would make it
very difficult to recruit to the trial. We could overcome this in future studies by having a great many more
recruitment sites and around five times as many participants, given that PI-IBS accounts for only around
20% of all cases of IBS-D, but this would require more resources than those that we had available to us.
It is worth noting that there is an appreciable loss to follow-up (15.5%) but this is not out of line with
other similar studies. Dropouts are mostly likely due to failure of treatment and so are unlikely to account
for our negative result.
Research recommendations
1. Our data suggest that it is unlikely that future trials of mesalazine in unselected IBS would be fruitful.
2. If there is a subgroup that may benefit it is likely to be those with postinfective IBS, particularly those
postinfective patients with more severe diarrhoea.
3. The link between mast cells and clinical symptoms is weak and, again, future work on the role of mast
cells needs to better characterise the patients, as the majority of unselected patients with IBS do not
have elevated mast cell numbers. It may be that, as others have reported, it is the number of activated
mast cells that are important53 and better markers of activation would be useful rather than the current
gold standard of electron microscopy, which is expensive and time-consuming.
4. Finally, the release of mediators from biopsies does not link well to symptoms or mast cell numbers. The
dominant factor for release is likely to be crushing and tissue injury by the biopsy process, which is not
well standardised and may overwhelm other factors that would be of more interest. We need a better
way of assessing in vivo activity of the mucosal cells.
DISCUSSION
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Chapter 9 Conclusions
This randomised placebo-controlled trial in 115 unselected patients with IBS-D showed that mesalazine4 g per day was no better than placebo in relieving the symptoms of abdominal pain or disturbed
bowel habit. However, contrary to the previous report in just 10 patients, mesalazine did not reduce mast
cell percentage area stained. Further post hoc analysis showed that raised calprotectin level was associated
with less psychological distress, implying a more gut-centred abnormality. A small subgroup of patients
with PI-IBS appeared to benefit but a larger adequately powered study is required to confirm this finding.
Further phenotyping of the heterogeneous group of patients with IBS-D is needed to allow better
evaluation of new treatments.
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Appendix 1 Excluded medication and
dose-controlled medication
P lease use in conjunction with the exclusion criteria definition.
Excluded medication
Non-steroidal anti-inflammatory drugs
Aceclofenac.
Acemetacin.
Aspirin.
Azapropazone.
Celecoxib.
Dexibuprofen.
Dexketoprofen.
Diclofenac sodium.
Etodolac.
Etoricoxib.
Fenbufen.
Fenoprofen.
Flurbiprofen.
Ibuprofen.
Indomethacin.
Ketoprofen.
Mefenamic acid.
Meloxicam.
Nabumetone.
Naproxen.
Piroxicam.
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Sulindac.
Tenoxicam.
Tiaprofenic acid.
Long-term antibiotic drugs
Please refer to the latest version of the British National Formulary.
Antispasmodic drugs
Alverine citrate.
Mebeverine hydrochloride.
Peppermint oil.
Antimuscarinic drugs
Atropine sulphate.
Dicycloverine hydrochloride.
Hyoscine butylbromide.
Propantheline bromide.
Opiates/antidiarrhoeal drugs
Codeine.
Loperamide.
Morphine.
Anti-inflammatory drugs
Prednisolone.
Budesonide.
Hydrocortisone.
Azathioprine.
Mercaptopurine.
5-aminosalicylic acid-containing medication
Balsalazide disodium.
Mesalazine.
Olsalazine sodium.
Sulfasalazine.
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Dose-controlled medication
Selective serotonin reuptake inhibitors
Citalopram.
Escitalopram.
Fluoxetine.
Fluvoxamine maleate.
Paroxetine.
Sertraline.
Tricyclic antidepressant drugs
Amitriptyline hydrochloride.
Clomipramine hydrochloride.
Dosulepin hydrochloride.
Doxepin.
Imipramine hydrochloride.
Lofepramine.
Nortriptyline.
Trimipramine.
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Appendix 2 Supplementary data
Methodology for immunohistochemical staining of cells for
mast cell tryptase, CD3+ T lymphocytes, CD68 and serotonin
Biopsies were formalin fixed and embedded in wax prior to standard sectioning for staining.
TABLE 14 Summary of antibodies used in immunohistochemistry
Antibody Supplier (order code) Dilution Pretreatment
Mast cell tryptase Dako (M7052) 1/500 l Protease 1–4 minutes
l Primary antibody for 32 minutes
l Roche ultraView detection kita plus Amplification kit
CD3 Leica (NCL-L-CD3–565) 1/50 l SCC1 (EDTA-based buffer) for 64 minutes
l Primary antibody for 32 minutes
l Roche ultraView detection kita plus Amplification kit
CD68 Dako (M0814) 1/2000 l SCC1 for 64 minutes
l Primary antibody for 32 minutes
l Roche ultraView detectiona
5-HT Dako (M0758) 1/400 l Protease 1 for 4 minutes
l Primary antibody for 32 minutes
l Roche ultraView detectiona
EDTA, ethylenediaminetetraacetic acid.
a Roche Diagnostics, Basel, Switzerland.
The slides prepared were scanned into the computer using the nanozoomer and was magnified ×40 for
ease of portability. Cell counting was performed by a single person (LTX, fellow from the FRAME
Laboratory, University of Nottingham) who was blinded to the study. Detection of each stained cell type
was checked for reproducibility (> 95%) before cell counting began. At least 5–10 areas around lamina
propria were drawn, and CD68 cells were counted, giving an average cell number per mm2. CD3, which
is a marker of lymphocytes, was assessed by counting the number of stained cells at the superficial
epithelium per area drawn (mm2) and an average obtained. The 5-HT cells were counted at the deep
lamina propria and an average of number of cells/mm2 were obtained. Mast cell tryptase expression was
detected in the lamina propria using automatic software (i-Tem Desktop, Olympus Soft Imaging Solutions
GMBH, Münster, Germany), as some mast cells may be in a degranulated state, thus making cell counting
difficult. Results were presented as the percentage area stained for mast cell tryptase.
Mast cell proteases (tryptase, chymase and CPA3) were measured by sandwich ELISA assays developed
by the Immunopharmacology Group, University of Southampton, as described previously.58–60 Briefly,
antibodies specific for tryptase (EAR), chymase (CC2) and CPA3 (CA2) were coated on Costar™ 96-well
EIA/RIA Plates (Fisher Scientific, Loughborough, UK) for 16 hours at +4 °C. Plates were washed three times
and blocked with 2% bovine serum albumin (BSA) for 1 hour at room temperature and samples or
protein standards of tryptase, chymase or CPA3 were added for 90 minutes. After a further washing
stage, detecting antibodies that were specific for tryptase (AA5), chymase (CC2) or CPA3 (CA5) were
added, the plates again washed, avidin–horseradish peroxidase added and cleavage of TMB substrate
(3,3′,5,5′-tetramethylbenzidine, Sigma-Aldrich, Gillingham, UK), measured colorimetrically at 450 nm.
Prior to assays being performed, the ELISA were validated for use with cell supernatants, by measuring
recovery of each of the proteases spiked into samples prior. Histamine (Life Science Format) was measured
using a commercially available enzyme immunoassay kit (ELISA, Neogen, Lexington, KY, USA). All assays
were performed blind.
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Adverse events
TABLE 15 Adverse events following randomisation
AE Mesalazine, na Placebo, n
Exacerbation of IBS (worsening abdominal pain and or diarrhoea) 2 3
Bloating 0 2
Dizziness 1 0
Chest pain 1 0
Rash 0 1
Discoloured urine 1 0
Pregnant 1 0
Flu-like illness 1 0
Breast cancer 1 0
a Mesalazine slow-release granule formulation (2 g; PENTASA®, Ferring Pharmaceuticals Ltd).
Recruitment
Recruitment was slow initially owing to other staff seeing patients and not being aware of the study.
The multiple visits were a deterrent and many patients said that they could not take time off work. We
advertised widely. Advertising on the local buses produced no volunteers but advertising in local free
papers produced a better response.
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Appendix 3 Abstract of oral presentation
Abstract accepted for oral presentation in the Digestive Disease Week 2014, Chicago, IL, USA.57
Reprinted from Gastroenterology volume 146 issue 5, Lam C, Tan W, Leighton M, Williams J, Agrawal A,
Sen S, et al. 712 A Multi-Centre, Parallel Group, Randomised Placebo Controlled Trial of Mesalazine for
Treatment of Diarrhoea-Predominant Irritable Bowel Syndrome (IBS-D). S23–S24, 2014 with permission
from Elsevier.
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Reprinted from Gastroenterology volume 146 issue 5, Lam C, Tan W, Leighton M, Williams J, Agrawal A, Sen S, et al. 712 A Multi-Centre, Parallel Group, Randomised Placebo
Controlled Trial of Mesalazine for Treatment of Diarrhoea-Predominant Irritable Bowel Syndrome (IBS-D). S23–S24, 2014 with permission from Elsevier.
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Appendix 4 Example of stool diary used, based
on the Bristol Stool Form Scale
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Stool diary
TABLE 18 Summary of number of days with stool diary entered at baseline and 11–12 weeks
Stool diary
Number of days with stool diary recorded,
mean (SD); median (IQR)
Baseline 13.9 (0.3); 14 (14–14)
11–12 weeks 13.8 (1.2); 14 (14–14)
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